Quarterly report pursuant to Section 13 or 15(d)

License Agreement with Duke - Additional Information (Detail)

v3.24.1.u1
License Agreement with Duke - Additional Information (Detail)
 3 Months Ended
Feb. 17, 2023
USD ($)
Patients
Feb. 04, 2022
USD ($)
Feb. 23, 2021
USD ($)
Feb. 29, 2024
USD ($)
ft²
shares
Nov. 30, 2023
USD ($)
Feb. 28, 2023
USD ($)
Feb. 23, 2023
USD ($)
Feb. 28, 2021
USD ($)
Dec. 01, 2020
USD ($)
Patent Option And Technology License Agreement [Line Items]                  
Revenue       $ 7,852,235   $ 7,824,415      
Impairment of assets         $ 13,108,064        
Duke University [Member]                  
Patent Option And Technology License Agreement [Line Items]                  
License fee payable             $ 2,000,000   $ 12,000,000
Milestone payments first phase III clinical trial   $ 2,000,000 $ 2,000,000            
Capitalized costs to obtain agreement               $ 15,372,382  
Present value of license fee       12,000,000          
Number of common stock value transferred       $ 3,585,172          
Number of common stock shares transferred | shares       409,734          
Capitalized costs amortization period       16 years          
Amortization expense       $ 0   240,193      
Duke University [Member] | 5.0% upon Execution of the Agreement [Member] | Fully Diluted Equity Ownership                  
Patent Option And Technology License Agreement [Line Items]                  
Common Stock Equal Full Diluted Equity Ownership Outstanding Percentage     5.00%            
Duke University [Member] | 2.5% Market Cap [Member] | Fully Diluted Equity Ownership                  
Patent Option And Technology License Agreement [Line Items]                  
Common Stock Equal Full Diluted Equity Ownership Outstanding Percentage     2.50%            
Duke University [Member] | Minimum [Member]                  
Patent Option And Technology License Agreement [Line Items]                  
Royalties Percentage Portion of Net Sales     7.00%            
Duke University [Member] | Minimum [Member] | 2.5% Market Cap Triggers with 18 Months [Member] | Fully Diluted Equity Ownership                  
Patent Option And Technology License Agreement [Line Items]                  
Average Closing Market Capital     $ 300,000,000            
Duke University [Member] | Minimum [Member] | 2.5% Market Cap Triggers with 24 Months [Member] | Fully Diluted Equity Ownership                  
Patent Option And Technology License Agreement [Line Items]                  
Average Closing Market Capital     $ 500,000,000            
Duke University [Member] | Maximum [Member]                  
Patent Option And Technology License Agreement [Line Items]                  
Royalties Percentage Portion of Net Sales     12.50%            
Duke University [Member] | Within Fourteen (14) days of February 23, 2021                  
Patent Option And Technology License Agreement [Line Items]                  
License fee payable     $ 10,000,000            
Duke University [Member] | Second Anniversary [Member]                  
Patent Option And Technology License Agreement [Line Items]                  
Minimum Annual Royalties Due Year Two     500,000            
Minimum Annual Royalties Due Year Three     1,000,000            
Minimum Annual Royalties Due Year Four     2,500,000            
Minimum Annual Royalties Due Year Five     5,000,000            
Minimum Annual Royalties Due After Year Five     $ 5,000,000            
Duke University [Member] | Third Anniversary [Member]                  
Patent Option And Technology License Agreement [Line Items]                  
Minimum Annual Royalties Due Year Three   500,000              
Minimum Annual Royalties Due Year Four   1,000,000              
Minimum Annual Royalties Due Year Five   2,500,000              
Minimum Annual Royalties Due Year Six   5,000,000              
Minimum Annual Royalties Due After Year Six   $ 5,000,000              
Duke University [Member] | Licensed Product and Licensed Process [Member]                  
Patent Option And Technology License Agreement [Line Items]                  
Area of medical condominium building | ft²       56,000          
Royalties Term       15 years          
Duke University [Member] | Licensed Product and Licensed Process [Member] | 2.5% Upon Cumulative Net Sales [Member] | Fully Diluted Equity Ownership                  
Patent Option And Technology License Agreement [Line Items]                  
Common Stock Equal Full Diluted Equity Ownership Outstanding Percentage     2.50%            
Revenue     $ 10,000,000            
Duke University [Member] | Licensed Product and Licensed Process [Member] | 2.5% Upon Cumulative Net Sales [Member] | Fully Diluted Equity Ownership                  
Patent Option And Technology License Agreement [Line Items]                  
Common Stock Equal Full Diluted Equity Ownership Outstanding Percentage     2.50%            
Revenue     $ 75,000,000            
Second Amendment to the License Agreement [Member]                  
Patent Option And Technology License Agreement [Line Items]                  
Payment towards funding and completion of study $ 2,000,000                
Research Agreement [Member]                  
Patent Option And Technology License Agreement [Line Items]                  
Additional Consideration Payable 2,000,000                
Monthly instalment payable 187,407                
Consideration payable for research $ 187,400                
Number of patients in trial's targeted accrual | Patients 137                
Emmes Biopharma Services [Member]                  
Patent Option And Technology License Agreement [Line Items]                  
License fee       $ 6,352,291          
Payment due on execution       100,000          
Management fee payable per month       $ 21,862          
License fee payment completion term       53 months          
Cost of trial estimated       $ 20,000,000          
Emmes Biopharma Services [Member] | Research and Development Expense [Member]                  
Patent Option And Technology License Agreement [Line Items]                  
Clinical trial expenses       $ 94,099   $ 0